Clinical Trial Update: Dasatinib (BMS-354825) in Subjects With Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating dasatinib in patients with chronic myeloid leukemia in blast crisis who were resistant or intolerant to imatinib; the study is complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Blast Crisis
• Chronic Myeloid Leukemia

Drugs mentioned

• DASATINIB (Dasatinib)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Chronic Myeloid Leukemia, Blast Crisis | Phase 2 | Status: COMPLETED | Results posted: 2010-03-02